MCID: ACR007
MIFTS: 63

Acromegaly

Categories: Endocrine diseases, Neuronal diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Acromegaly

MalaCards integrated aliases for Acromegaly:

Name: Acromegaly 11 19 58 75 53 43 14 16 71
Gigantism 19 75 53 71
Growth Hormone-Secreting Pituitary Adenoma 71
Growth Hormone Excess 19
Somatotroph Adenoma 19
Pituitary Giant 19

Characteristics:


Prevelance:

1-9/1000000 (Worldwide, Belgium, Ireland, Finland, Korea, Republic of, Iceland, Malta, Sweden, Denmark) 1-9/100000 (Spain, Italy, United Kingdom, Ireland, Korea, Republic of, United States, United States, Denmark, Worldwide) 1-5/10000 (Belgium, Iceland, Malta) 58

Age Of Onset:

Adolescent,Adult,Childhood,Elderly,Infancy 58

Classifications:

Orphanet: 58  
Rare infertility disorders
Rare endocrine diseases


Summaries for Acromegaly

GARD: 19 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that; alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain stimulating the pituitary gland to produce GH. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than Acromegaly. Acromegaly may also be part of other genetic syndromes such as multiple endocrine neoplasia syndrome type 1 and type 4, hereditary paraganglioma-pheochromocytoma syndrome, McCune-Allright syndrome, neurofibromatosis or Carney complex.

MalaCards based summary: Acromegaly, also known as gigantism, is related to pituitary adenoma 1, multiple types and pituitary tumors, and has symptoms including endocrine system signs and symptoms An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are GPCR downstream signalling and Class A/1 (Rhodopsin-like receptors). The drugs Metformin and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and bone, and related phenotypes are hyperhidrosis and macroglossia

Orphanet: 58 A rare acquired endocrine disease related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.

Disease Ontology: 11 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia 75 Acromegaly: Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Gigantism: Gigantism (Greek: γίγας, gígas, "giant", plural γίγαντες, gígantes), also known as giantism, is a... more...

Related Diseases for Acromegaly

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1071)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 1, multiple types 32.4 SST PRL MEN1 IGFBP3 IGF1 GH1
2 pituitary tumors 31.8 SSTR5 SST PRL MEN1 IGF1 GNAS
3 tsh producing pituitary tumor 31.6 SSTR5 SST PRL POMC GPR101 AIP
4 insulin-like growth factor i 31.3 SST PRL INS IGFBP3 IGFBP1 IGF1
5 sleep apnea 31.3 INS IGF1 GHRL
6 apnea, obstructive sleep 31.2 POMC INS IGF1 GHRL
7 hypogonadism 31.2 PRL POMC INS IGF1 GH1
8 galactorrhea 31.2 PRL IGF1
9 carney complex variant 31.2 SST PRL POMC MEN1 IGF1 GPR101
10 mccune-albright syndrome 31.2 SST PRL POMC MEN1 IGF1 GPR101
11 diabetes insipidus 31.1 PRL POMC INS GH1
12 goiter 31.1 TRH SST PRL INS IGF1 GNAS
13 prediabetes syndrome 31.1 INS IGFBP3 IGFBP1 IGF1 GHRL GH1
14 carcinoid tumors, intestinal 31.1 SSTR2 SST MEN1
15 graves disease 1 31.1 TRH POMC INS
16 carcinoid syndrome 31.1 SST IGF1 GHRH
17 pituitary-dependent cushing's disease 31.1 TRH SST PRL POMC GHRH GH1
18 central diabetes insipidus 31.0 TRH PRL POMC IGF1 GH1
19 premature ovarian failure 7 31.0 POMC GH1
20 hypopituitarism 31.0 TRH PRL POMC INS IGFBP3 IGF1
21 hyperglycemia 31.0 SST INS IGF1 GHRL GH1
22 adenoma 30.9 TRH SSTR5 SSTR2 SST PRL POMC
23 hyperprolactinemia 30.9 TRH SST PRL POMC INS IGF1
24 fibrous dysplasia 30.8 SST PRL IGF1 GNAS GHRH GH1
25 pituitary apoplexy 30.8 TRH SST PRL POMC INS IGF1
26 glucose intolerance 30.8 SST PRL POMC INS IGFBP1 IGF1
27 amenorrhea 30.8 TRH PRL POMC INS IGF1 GHRL
28 empty sella syndrome 30.8 TRH PRL POMC INS IGFBP3 IGF1
29 acanthosis nigricans 30.8 INS IGF1 GH1
30 growth hormone secreting pituitary adenoma 30.8 SSTR5 SSTR2 SSTR1 SST PRL POMC
31 lipid metabolism disorder 30.7 POMC INS IGF1 GHRL
32 skin tag 30.7 PRL INS IGFBP3 IGF1
33 gangliocytoma 30.7 SST PRL POMC GHRH
34 chromophobe adenoma 30.7 TRH PRL POMC GH1
35 type 2 diabetes mellitus 30.6 SST PRL POMC INS IGFBP3 IGFBP1
36 multiple endocrine neoplasia 30.6 SST PRL POMC MEN1 GNAS AIP
37 central precocious puberty 30.6 POMC IGFBP3 IGF1
38 hyperinsulinism 30.6 SST INS IGFBP3 IGFBP1 IGF1 GHRL
39 neuroendocrine tumor 30.6 SSTR2 SST POMC MEN1 IGF1 GHRL
40 leptin deficiency or dysfunction 30.6 TRH POMC INS IGF1 GHRL GHRH
41 hypothyroidism, congenital, nongoitrous, 4 30.5 PRL POMC IGF1 GH1
42 hypogonadotropic hypogonadism 30.5 PRL POMC INS IGF1
43 sleep disorder 30.5 POMC INS IGF1 GHRL
44 irritable bowel syndrome 30.5 SST POMC GHRL
45 gestational diabetes 30.5 PRL INS IGFBP1 IGF1 GHRL GHR
46 conn's syndrome 30.5 TRH SST PRL POMC MEN1 INS
47 pituitary adenoma 30.5 TRH SSTR5 SSTR2 SSTR1 SST PRL
48 hyperthyroidism 30.5 TRH SST PRL POMC INS IGF1
49 hypothyroidism 30.4 TRH SST PRL POMC INS IGFBP3
50 turner syndrome 30.4 INS IGFBP3 IGFBP1 IGF1 GHR GH1

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to Acromegaly

Symptoms & Phenotypes for Acromegaly

Human phenotypes related to Acromegaly:

58 30 (show top 50) (show all 63)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000975
2 macroglossia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000158
3 coarse facial features 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000280
4 macrotia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000400
5 mandibular prognathia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000303
6 fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012378
7 full cheeks 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000293
8 thick lower lip vermilion 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000179
9 anterior hypopituitarism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000830
10 arthralgia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002829
11 long face 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000276
12 joint swelling 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001386
13 broad forehead 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000337
14 osteoarthritis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002758
15 tall stature 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000098
16 wide nose 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000445
17 large hands 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001176
18 tapered finger 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001182
19 long penis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000040
20 broad foot 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001769
21 deep plantar creases 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001869
22 cortical diaphyseal thickening of the upper limbs 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003859
23 macrodactyly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004099
24 deep palmar crease 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006191
25 pituitary growth hormone cell adenoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011760
26 elevated circulating growth hormone concentration 30 Hallmark (90%) HP:0000845
27 frontal bossing 58 30 Frequent (33%) Frequent (79-30%)
HP:0002007
28 depression 58 30 Frequent (33%) Frequent (79-30%)
HP:0000716
29 kyphosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002808
30 sleep apnea 58 30 Frequent (33%) Frequent (79-30%)
HP:0010535
31 diabetes mellitus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000819
32 hypertension 58 30 Frequent (33%) Frequent (79-30%)
HP:0000822
33 widely spaced teeth 58 30 Frequent (33%) Frequent (79-30%)
HP:0000687
34 anxiety 58 30 Frequent (33%) Frequent (79-30%)
HP:0000739
35 abnormal fingernail morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0001231
36 palpebral edema 58 30 Frequent (33%) Frequent (79-30%)
HP:0100540
37 generalized hirsutism 58 30 Frequent (33%) Frequent (79-30%)
HP:0002230
38 paresthesia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003401
39 spinal canal stenosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0003416
40 hoarse voice 58 30 Frequent (33%) Frequent (79-30%)
HP:0001609
41 migraine 58 30 Frequent (33%) Frequent (79-30%)
HP:0002076
42 cerebral palsy 58 30 Frequent (33%) Frequent (79-30%)
HP:0100021
43 synophrys 58 30 Frequent (33%) Frequent (79-30%)
HP:0000664
44 abnormal toenail morphology 58 30 Frequent (33%) Frequent (79-30%)
HP:0008388
45 broad jaw 58 30 Frequent (33%) Frequent (79-30%)
HP:0012802
46 dysmenorrhea 58 30 Frequent (33%) Frequent (79-30%)
HP:0100607
47 hypogonadotropic hypogonadism 30 Frequent (33%) HP:0000044
48 acne 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001061
49 hypertrophic cardiomyopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001639
50 mitral regurgitation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001653

UMLS symptoms related to Acromegaly:


endocrine system signs and symptoms

GenomeRNAi Phenotypes related to Acromegaly according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 AIP GH1 GHR GHRH GHRHR GHRL
2 no effect GR00402-S-2 10.19 AIP GH1 GHR GHRHR GHRL GNAS
3 Reduced mammosphere formation GR00396-S 9.5 GHR GHRL GNAS IGF1 IGFBP3 MEN1

MGI Mouse Phenotypes related to Acromegaly:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.39 GH1 GHR GHRH GHRHR GNAS IGF1
2 homeostasis/metabolism MP:0005376 10.39 AIP GH1 GHR GHRH GHRHR GHRL
3 growth/size/body region MP:0005378 10.28 AIP GH1 GHR GHRH GHRHR GNAS
4 endocrine/exocrine gland MP:0005379 10.24 AIP GH1 GHR GHRH GHRHR GHRL
5 liver/biliary system MP:0005370 10.22 AIP GH1 GHR GHRH GNAS IGFBP1
6 adipose tissue MP:0005375 10.2 GH1 GHR GHRH GHRHR GHRL GNAS
7 behavior/neurological MP:0005386 10.19 GH1 GHR GHRH GHRHR GHRL GNAS
8 cardiovascular system MP:0005385 10.13 AIP GH1 GHR GHRH GHRHR GNAS
9 renal/urinary system MP:0005367 10.1 GH1 GHR GNAS IGF1 INS POMC
10 immune system MP:0005387 9.97 GH1 GHR GHRH GHRHR GNAS IGF1
11 skeleton MP:0005390 9.65 GHR GHRH GHRHR GNAS IGF1 IGFBP3
12 integument MP:0010771 9.32 AIP GHR GHRHR GNAS IGF1 IGFBP3

Drugs & Therapeutics for Acromegaly

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
2
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
3
Cabergoline Approved Phase 4 81409-90-7 54746
4
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
5
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
6
Lactitol Approved, Investigational Phase 4 585-86-4 157355
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
9
Lanreotide Approved Phase 4 108736-35-2 71349 6918011
10 Insulin, Globin Zinc Phase 4
11
Insulin Phase 4
12
Sitagliptin Phosphate Phase 4 654671-77-9
13 HIV Protease Inhibitors Phase 4
14 Hypoglycemic Agents Phase 4
15 Dipeptidyl-Peptidase IV Inhibitors Phase 4
16 Incretins Phase 4
17
protease inhibitors Phase 4
18 Cardiotonic Agents Phase 4
19 Sympathomimetics Phase 4
20 Protective Agents Phase 4
21 Hormones Phase 4
22 Hormone Antagonists Phase 4
23 Dopamine agonists Phase 4
24 Dopamine Agents Phase 4
25 Neurotransmitter Agents Phase 4
26 Antiparkinson Agents Phase 4
27 Antineoplastic Agents, Hormonal Phase 4
28 Gastrointestinal Agents Phase 4
29 Liver Extracts Phase 4
30
Sorbitol Approved, Investigational Phase 3 69-65-8, 50-70-4 453 6251 5780
31 Carboxymethylcellulose Sodium Phase 3
32 Pharmaceutical Solutions Phase 3
33
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
34
Sodium citrate Approved, Investigational Phase 2 68-04-2 23431961
35
Clomifene Approved, Investigational Phase 2 911-45-5 2800
36
Dimenhydrinate Approved Phase 2 523-87-5 10660
37
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
38
Enclomiphene Investigational Phase 2 15690-57-0 1548953
39 Phosphodiesterase Inhibitors Phase 2
40 Phosphodiesterase 5 Inhibitors Phase 2
41 Vasodilator Agents Phase 2
42 Ethinyl estradiol, levonorgestrel drug combination Phase 2
43 Mitogens Phase 2
44 Estrogens Phase 2
45 Estrogen Receptor Modulators Phase 2
46 Estrogen Receptor Antagonists Phase 2
47 Estrogen Antagonists Phase 2
48 Zuclomiphene Phase 2
49 Citrate Phase 2
50 Selective Estrogen Receptor Modulators Phase 2

Interventional clinical trials:

(show top 50) (show all 185)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
2 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant: an Open-labelled, Prospective Study Unknown status NCT00552851 Phase 4 pegvisomant
3 Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range Unknown status NCT01424241 Phase 4 Sandostatin LAR
4 Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study Unknown status NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
5 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
6 Beneficial Effect of Dose Escalation of Octreotide-LAR as First-Line Therapy in Patients With Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
7 Study to Determine Whether Ultrasound Guidance Improves Delivery and Efficacy of Intramuscular Injection of Long-Acting Octreotide in the Treatment of Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
8 A Phase IV, Multicentre, Open Label, Controlled Study to Assess the Ability of Patients With Acromegaly, or Their Partners, to Administer Somatuline Autogel. Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
9 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction - A Twelve Month Randomized Cross-Over Study in Patients With Acromegaly Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
10 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
11 The Effect of Acute Application of Pegvisomant Alone and in Combination With Octreotide on Endogenous GH Levels During a 6 Hour Test in Patients With Acromegaly on Constant Pegvisomant Treatment Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
12 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
13 A Multicenter, Open, Prospective, Observational Study to Investigate the Effect of Lanreotide Autogel 120 mg on Control of GH and IGF-I Excess and Tumor Shrinkage in Newly Diagnosed Patients With Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
14 A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
15 A Phase IV, Open-label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel® in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
16 Does Surgical Debulking Of Pituitary Adenomas Improve Responsiveness To Octreotide LAR In The Treatment Of Acromegaly: An Investigator-Initiated Study Completed NCT01371643 Phase 4 Octreotide LAR
17 A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
18 The Effects of Weekly Administration of 40 mg Pegvisomant or Placebo on Quality of Life and Insulin Sensitivity in Acromegalic Patients With Normal IGF-I Concentrations During Long-Term Treatment With Long-Acting Somatostatin Analogs Completed NCT00642720 Phase 4 Pegvisomant
19 Preoperative Octreotide Treatment of Patients With Growth Hormone Producing Pituitary Adenomas Completed NCT00521300 Phase 4 Octreotide
20 A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program. Completed NCT00151437 Phase 4 Pegvisomant treatment
21 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
22 A Multicenter, Single Arm, Proof of Concept Study to Investigate the Efficacy of an 8 Month Combination Therapy of Octreotide and Cabergoline in Acromegalic Patients Only Partially Responsive to Somatostatin Analog Monotherapy Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
23 An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
24 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline
25 Open Label Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
26 A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity Terminated NCT01861717 Phase 4 lanreotide
27 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment Unknown status NCT03252353 Phase 3 octreotide capsules;Matching placebo
28 A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands Completed NCT02685709 Phase 3 Octreotide capsules
29 Strict IGF-1 Control in Acromegaly (I-Con Study) Completed NCT02952885 Phase 3 Pegvisomant
30 A Multi Center Open Label Study to Assess the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
31 Phase III, Multicentre, Open Clinical Study on the Efficacy and Tolerability of a New Slow-release Formulation of Lanreotide (Autogel 120 mg) in Patients With Active Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
32 A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed NCT02354508 Phase 3 Pasireotide LAR
33 A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
34 A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
35 Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG - Completed NCT00143416 Phase 3 Pegvisomant
36 A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
37 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3 Octreotide LAR
38 Efficacy and Safety of Oral Octreolin™ in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs Completed NCT01412424 Phase 3 Octreotide capsules
39 Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
40 A Phase III, Multicentre, Open Label, Comparative, Dose-interval Titration Study Evaluating the Efficacy and Safety of Six Repeated Deep Subcutaneous Administrations of Lanreotide Autogel 120mg, in Acromegalic Patients Previously Treated With Octreotide LAR Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
41 Phase III, Multicentre, Open Study to Assess the Efficacy and Safety Profiles of the Co-administration of Lanreotide Autogel 120 mg (Administered Via Deep Subcutaneous Injections Every 28 Days) and Pegvisomant 40 to 120 mg Per Week (Administered Via Subcutaneous Route Once or Twice a Week) in Acromegalic Patients Failing to Respond to Lanreotide Autogel 120 mg Alone Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
42 A Randomised, Open-label, Multicenter Study Comparing the Efficacy and Safety of Medical Treatment With Octreotide Acetate 30 mg Administered Every 21 Days for 6 Months With That of Octreotide Acetate 60 mg Administered Every 28 Days for 6 Months in Acromegalic Patients With Uncontrolled Disease Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
43 Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
44 Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3 Octreotide LAR
45 Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
46 Phase II, Multicentre, Randomized, Double-blind Study in Acromegalic Patients Evaluating the Efficacy and Safety of a Single Deep Subcutaneous Administration of Lanreotide Autogel (60, 90 or 120mg) Versus Placebo Followed by a Single Blind Fixed Dose Phase Evaluating the Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Profile of Multiple Deep Subcutaneous Administrations of Lanreotide Autogel (60, 90 & 120mg) Ending in Open Label Dose Titration Phase. Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)
47 Phase III, Multicentre, Open Study to Assess the Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Previously Treated or Not by Somatostatin Analogues. Completed NCT00210457 Phase 3 Lanreotide (Autogel formulation)
48 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
49 A Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly Recruiting NCT04125836 Phase 3 CAM2029 (octreotide subcutaneous depot)
50 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly Recruiting NCT04076462 Phase 3 CAM2029 (octreotide subcutaneous depot);Matching placebo

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS 71 / NDF-RT 50 :


2-Bromoergocryptine Mesylate
Bromocriptine
lanreotide
Octreotide
Octreotide Acetate
pegvisomant

Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

Anatomical Context for Acromegaly

Organs/tissues related to Acromegaly:

FMA: Limb
MalaCards : Pituitary, Bone, Pancreas, Brain, Skin, Olfactory Bulb, Skeletal Muscle

Publications for Acromegaly

Articles related to Acromegaly:

(show top 50) (show all 10048)
# Title Authors PMID Year
1
IGF-I stimulates reactive oxygen species (ROS) production and inhibits insulin-dependent glucose uptake via ROS in 3T3-L1 adipocytes. 53 62
20185348 2010
2
Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. 53 62
20215398 2010
3
Dose optimization of somatostatin analogues for acromegaly patients. 53 62
20348838 2010
4
Skin reaction and fever after treatment with pegvisomant in a patient with acromegaly. 53 62
20206782 2010
5
Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. 53 62
19965922 2010
6
The current status of IGF-I assays--a 2009 update. 53 62
19818658 2010
7
Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. 53 62
19890024 2010
8
Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity. 53 62
19798623 2010
9
Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly. 53 62
19880791 2010
10
The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. 53 62
19850678 2010
11
Reduction of elevated IGF-1 levels in coincident amyotrophic lateral sclerosis and acromegaly. 53 62
19634028 2010
12
From somatostatin to octreotide LAR: evolution of a somatostatin analogue. 53 62
19842996 2009
13
A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly. 53 62
20003832 2009
14
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. 53 62
20009494 2009
15
Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. 53 62
19773369 2009
16
The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly. 53 62
19864451 2009
17
Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. 53 62
19852525 2009
18
A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. 53 62
19723758 2009
19
Long term effect of external pituitary irradiation on IGF1 levels in patients with acromegaly free of adjunctive treatment. 53 62
19661126 2009
20
Somatostatin analog and pegvisomant combination therapy for acromegaly. 53 62
19763127 2009
21
Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. 53 62
19622615 2009
22
[Treatment of pituitary adenomas]. 53 62
19758960 2009
23
Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. 53 62
19509108 2009
24
Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? 53 62
19226264 2009
25
[AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature]. 53 62
19883897 2009
26
Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice. 53 62
19491373 2009
27
D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. 53 62
19439509 2009
28
Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. 53 62
19094074 2009
29
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. 53 62
19491229 2009
30
[Outcome of somatostatin analogue treatment in acromegaly]. 53 62
19617182 2009
31
Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country. 53 62
18440607 2009
32
Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. 53 62
19366854 2009
33
Successful use of weekly pegvisomant administration in patients with acromegaly. 53 62
19411301 2009
34
Factors determining inadequate hypoglycaemia during insulin tolerance testing (ITT) after pituitary surgery. 53 62
19178524 2009
35
Association between serum insulin-like growth factor (IGF) I and IGF binding protein-3 and lung function. 53 62
19401363 2009
36
Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly. 53 62
19494714 2009
37
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. 53 62
19322513 2009
38
Lanreotide for the treatment of acromegaly. 53 62
19533047 2009
39
Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly. 53 62
19527094 2009
40
Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. 53 62
19336510 2009
41
The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. 53 62
19109045 2009
42
Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. 53 62
19208728 2009
43
Growth hormone receptor exon 3 isoforms and their implication in growth disorders and treatment. 53 62
19407498 2009
44
Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. 53 62
19158203 2009
45
Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. 53 62
19240267 2009
46
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. 53 62
19542735 2009
47
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. 53 62
19001517 2009
48
Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies. 53 62
19017754 2009
49
Serum ghrelin levels and disturbances of the lipid profile in patients with acromegaly. 53 62
19675514 2009
50
Pituitary-hormone secretion by thyrotropinomas. 53 62
19051037 2009

Variations for Acromegaly

Expression for Acromegaly

Search GEO for disease gene expression data for Acromegaly.

Pathways for Acromegaly

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 GHRH GHRHR GHRL GNAS POMC SST
2
Show member pathways
12.98 GHRH GHRHR GHRL GNAS POMC SST
3 12.85 TRH SSTR5 SSTR2 SSTR1 SST POMC
4
Show member pathways
12.75 PRL INS IGF1 GHR GH1
5
Show member pathways
12.53 GH1 GHR IGF1 IGFBP3 INS
6
Show member pathways
12.44 POMC GNAS GHRHR GHRH GH1
7
Show member pathways
12.16 MEN1 IGFBP3 IGFBP1 IGF1
8
Show member pathways
11.95 POMC INS IGF1 GHRL GH1
9
Show member pathways
11.94 POMC GNAS GHRHR GHRH
10 11.72 INS IGFBP3 IGF1
11 11.66 INS IGFBP3 IGF1
12 11.53 IGF1 GNAS GHRH GH1
13 11.34 POMC INS GHRL GHRH
14
Show member pathways
11.17 PRL GHR GH1
15 10.56 PRL POMC INS GHRL

GO Terms for Acromegaly

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.3 GH1 GHR GHRH GHRL IGF1 IGFBP1
2 endoplasmic reticulum lumen GO:0005788 10.1 MEN1 INS IGFBP3 IGFBP1 GHRL
3 extracellular region GO:0005576 9.72 GH1 GHR GHRH GHRL GNAS IGF1
4 insulin-like growth factor ternary complex GO:0042567 9.67 IGFBP3 IGF1
5 insulin-like growth factor binding protein complex GO:0016942 9.62 IGFBP3 IGF1
6 growth hormone receptor complex GO:0070195 9.46 GHR GH1
7 endosome lumen GO:0031904 9.43 PRL INS GH1

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.3 IGFBP3 MEN1 SST SSTR1 SSTR2 SSTR5
2 G protein-coupled receptor signaling pathway GO:0007186 10.25 SSTR5 SSTR2 SSTR1 SST INS GPR101
3 cell-cell signaling GO:0007267 10.19 TRH SST POMC INS GHRH
4 positive regulation of MAPK cascade GO:0043410 10.18 INS IGFBP3 IGF1 GHRL
5 neuropeptide signaling pathway GO:0007218 10.11 SSTR5 SSTR2 SSTR1 POMC
6 signal transduction GO:0007165 10.09 GH1 GHRHR GNAS GPR101 IGF1 IGFBP1
7 hormone-mediated signaling pathway GO:0009755 10.02 TRH GHRL GHR
8 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.01 PRL GHR GH1
9 regulation of multicellular organism growth GO:0040014 9.93 PRL IGF1 GHR
10 positive regulation of growth hormone secretion GO:0060124 9.91 GHRH GHRHR GHRL
11 growth hormone secretion GO:0030252 9.8 GHRL GHRHR GHRH
12 positive regulation of circadian sleep/wake cycle, non-REM sleep GO:0046010 9.78 GHRL GHRHR
13 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.77 GHRHR IGFBP1 IGFBP3
14 adenohypophysis development GO:0021984 9.74 GHRHR GHRH
15 somatostatin signaling pathway GO:0038170 9.73 SSTR5 SSTR2 SSTR1
16 positive regulation of multicellular organism growth GO:0040018 9.65 GHRL GHRHR GHRH GHR GH1
17 hormone secretion GO:0046879 9.56 GHRHR GHRH
18 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.32 IGFBP3 IGF1 GHRHR GHRH GH1

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide binding GO:0042923 9.88 SSTR5 SSTR2 SSTR1
2 insulin-like growth factor II binding GO:0031995 9.73 IGFBP3 IGFBP1
3 insulin-like growth factor receptor binding GO:0005159 9.73 INS IGF1 GNAS
4 growth hormone-releasing hormone activity GO:0016608 9.67 GHRL GHRH
5 growth factor binding GO:0019838 9.63 GHR GHRHR IGFBP1 IGFBP3
6 prolactin receptor binding GO:0005148 9.62 PRL GH1
7 hormone activity GO:0005179 9.5 TRH SST PRL POMC INS IGF1
8 somatostatin receptor activity GO:0004994 9.43 SSTR5 SSTR2 SSTR1

Sources for Acromegaly

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....